https://www.nasdaq.com/press-release/brickell-biotech-reports-third-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-third-quarter-2021-financial-results-and-provide-a
https://www.nasdaq.com/press-release/brickell-biotech-prices-public-offering-of-common-stock-2021-10-28
https://www.nasdaq.com/press-release/brickell-biotech-announces-proposed-underwritten-public-offering-of-common-stock-2021
https://www.nasdaq.com/press-release/brickell-biotech-announces-positive-topline-results-achieving-statistical
https://www.nasdaq.com/press-release/brickell-biotech-to-host-key-opinion-leader-webinar-on-dyrk1a-and-its-role-in
https://www.nasdaq.com/press-release/brickell-biotech-to-participate-at-upcoming-september-conferences-2021-09-08
https://www.nasdaq.com/press-release/brickell-biotech-expands-leadership-team-appointing-dr.-monica-luchi-as-chief-medical
https://www.nasdaq.com/press-release/brickell-biotech-acquires-exclusive-rights-to-phase-1-ready-dyrk1a-inhibitor-program
https://www.nasdaq.com/press-release/brickell-biotech-announces-final-patient-completed-second-u.s.-phase-3-pivotal
https://www.nasdaq.com/press-release/brickell-biotech-reports-second-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-second-quarter-2021-financial-results-and-provide-a
https://www.nasdaq.com/press-release/brickell-biotech-announces-closing-of-%248.05-million-bought-deal-offering-of-common
https://www.nasdaq.com/press-release/brickell-biotech-increases-previously-announced-bought-deal-offering-of-common-stock
https://www.nasdaq.com/press-release/brickell-biotech-announces-%245.0-million-bought-deal-offering-of-common-stock-2021-07
https://www.nasdaq.com/press-release/brickell-biotech-to-participate-at-william-blairs-biotech-focus-conference-2021-2021
https://www.nasdaq.com/press-release/brickell-biotech-announces-final-patient-completed-in-first-u.s.-phase-3-pivotal
https://www.nasdaq.com/press-release/brickell-biotech-announces-initiation-of-a-phase-1-study-of-sofpironium-bromide-gel
https://www.nasdaq.com/press-release/brickell-biotech-announces-publication-of-japan-phase-3-long-term-safety-and-efficacy
https://www.nasdaq.com/press-release/brickell-biotech-reports-first-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-first-quarter-2021-financial-results-and-provide-a
https://www.nasdaq.com/press-release/brickell-biotech-completes-patient-enrollment-in-u.s.-phase-3-pivotal-cardigan-i
https://www.nasdaq.com/press-release/brickell-biotech-reports-results-from-u.s.-phase-3-open-label-long-term-safety-study
https://www.nasdaq.com/press-release/brickell-biotech-announces-presentation-of-us-phase-3-open-label-long-term-safety
https://www.nasdaq.com/press-release/brickell-biotech-announces-publication-of-its-hdsm-ax-patient-reported-outcome-scale
https://www.nasdaq.com/press-release/brickell-biotech-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/brickell-biotech-to-host-key-opinion-leader-webinar-on-the-hyperhidrosis-market-2021
https://www.nasdaq.com/press-release/brickell-biotech-to-participate-in-march-virtual-investor-conferences-2021-02-25
https://www.nasdaq.com/press-release/brickell-biotech-to-report-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/brickell-biotech-announces-publication-of-japan-pivotal-phase-3-study-results-for
https://www.nasdaq.com/press-release/brickell-biotech-doses-first-patient-in-second-u.s.-pivotal-phase-3-clinical-study
https://www.nasdaq.com/press-release/brickell-biotech-announces-launch-date-for-sofpironium-bromide-gel-5-ecclockr-in
https://www.nasdaq.com/press-release/brickell-biotech-to-present-at-piper-sandler-32nd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/brickell-biotech-reports-third-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-third-quarter-2020-financial-results-and-provide-a
https://www.nasdaq.com/press-release/brickell-biotech-announces-pricing-of-%2415.0-million-underwritten-public-offering-2020
https://www.nasdaq.com/press-release/brickell-biotech-announces-initiation-of-u.s.-phase-3-program-evaluating-sofpironium
https://www.nasdaq.com/press-release/brickell-biotech-announces-approval-of-sofpironium-bromide-gel-5-in-japan-for
https://www.nasdaq.com/press-release/brickell-biotech-to-participate-in-september-virtual-investor-conferences-2020-09-10
https://www.nasdaq.com/press-release/anges-and-brickell-biotech-announce-a-collaboration-agreement-for-the-development-of
https://www.nasdaq.com/press-release/brickell-biotech-announces-issuance-of-new-composition-of-matter-patent-on
https://www.nasdaq.com/press-release/brickell-biotech-reports-second-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-second-quarter-2020-financial-results-and-provide-a
https://www.nasdaq.com/press-release/brickell-biotech-inc.-announces-pricing-of-%2420.1-million-underwritten-public-offering
https://www.nasdaq.com/press-release/brickell-biotech-announces-positive-phase-3-pivotal-study-results-for-sofpironium
https://www.nasdaq.com/press-release/brickell-biotech-reports-first-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-to-report-first-quarter-2020-financial-results-on-may-13-2020-2020
https://www.nasdaq.com/press-release/brickell-biotech-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/brickell-biotech-to-report-fourth-quarter-and-full-year-2019-financial-results-on
https://www.nasdaq.com/press-release/brickell-biotech-announces-late-breaking-oral-presentation-at-2020-american-academy
https://www.nasdaq.com/press-release/brickell-biotech-announces-publication-of-its-u.s.-phase-2b-study-results-for
https://www.nasdaq.com/press-release/brickell-biotech-announces-settlement-of-dispute-with-bodor-labs-and-entry-into
https://www.nasdaq.com/press-release/brickell-bios-development-partner-kaken-pharmaceutical-submits-new-drug-application
https://www.nasdaq.com/press-release/brickell-bio-announces-third-quarter-2019-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/brickell-biotech-provides-update-on-bodor-labs-complaint-and-funding-agreement-with
https://www.nasdaq.com/press-release/moore-kuehn-pllc-encourages-vical-incorporated-vicl-asv-holdings-inc.-asv-pcm-inc.
